|
Eine Ebene nach oben |
Gruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 12
Zeitschriftenartikel
Müller, V.; Banys-Paluchowski, M.; Friedl, T. W. P.; Fasching, P. A.; Schneeweiss, A.; Hartkopf, A.; Wallwiener, D.; Rack, B.; Meier-Stiegen, F.; Huober, J.; Rübner, M.; Hoffmann, O.; Müller, L.; Janni, W.; Wimberger, P.; Jäger, B.; Pantel, K.; Riethdorf, S.; Harbeck, N. und Fehm, T.
(2021):
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program.
In: Esmo Open, Bd. 6, Nr. 6
Jäger, B. A. S.; Neugebauer, J.; Andergassen, U.; Melcher, C.; Schochter, F.; Mouarrawy, D.; Ziemendorff, G.; Clemens, M.; Abel, E. v.; Heinrich, G.; Schüller, K.; Schneeweiss, A.; Fasching, P.; Beckmann, M. W.; Scholz, Ch.; Friedl, T. W. P.; Friese, K.; Pantel, K.; Fehm, T.; Janni, W. und Rack, B.
(2017):
The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial.
In: PLOS One 12(6), e0173593 [PDF, 1MB]
In: PLOS One 12(6), e0173593 [PDF, 1MB]
Janni, W.; Rack, B.; Häberle, L.; Friedl, T. W. P.; Tesch, H.; Lorenz, R.; Jäger, B.; Fehm, T.; Müller, V.; Schneeweiß, A.; Lichtenegger, W.; Blohmer, J.; Beckmann, M. W.; Scholz, C.; Pantel, K.; Trapp, E. und Fasching, P. A.
(2017):
Active surveillance with a combination of tumor marker CA27.29 and detection of circulating tumor cells two year after primary diagnosis strongly predicts subsequent prognosis.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
DETECT III and IV - Individualized CTC-based therapy of metastatic breast cancer.
In: Cancer Research, Bd. 77
Polasik, A.; Schramm, A.; Friedl, T. W. P.; Rack, B.; Trapp, E.; Tzschaschel, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Pantel, K.; Meier-Stiegen, F.; Wimberger, P.; Janni, W. und Fehm, T.
(2017):
The DETECT V-study - Comparison of dual HER2-targeted therapy with trastuzumab plus pertuzumab in combination with chemo-or endocrine therapy in patients with HER2-positive and hormone-receptor positive metastatic breast cancer.
In: Cancer Research, Bd. 77
Tzschaschel, M. L. J.; Rack, B.; Majunke, L.; Trapp, E. K.; Mahner, S.; Fasching, P. A.; Fehm, T.; Schneeweiss, A.; Friedl, T. W. P.; Polasik, A.; Janni, W. und Alunni-Fabbroni, M.
(2017):
Profiling miRNA in high risk postoperative early breast cancer patients to detect possible association to correlation with immune system antitumor response.
In: Cancer Research, Bd. 77
Tzschaschel, M. L. J.; Rack, B.; Andergassen, U.; Friedl, T. W. P.; Schneeweiss, A.; Müller, V.; Tanja, F.; Pantel, K.; Gade, J.; Lorenz, R.; Rezai, M.; Tesch, H.; Soeling, U.; Polasik, A.; Alunni-Fabbroni, M.; Trapp, E. K.; Mahner, S.; Schindlbeck, C.; Lichtenegger, W.; Beckmann, M. W.; Fasching, P. A. und Janni, W.
(2017):
Dynamics of circulating tumor cells during the course of chemotherapy and prognostic relevance across molecular subtypes in high-risk early breast cancer patients Results from the adjuvant SUCCESS A trial.
In: Cancer Research, Bd. 77
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, F.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hartkopf, A.; Schneeweiss, A.; Müller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Predictors for discordance in HER2 phenotype between primary tumor and circulating tumor cells in women with metastatic breast cancer.
In: Cancer Research, Bd. 76
Schröder, L.; Rack, B.; Sommer, H.; Koch, J. G.; Weissenbacher, T.; Janni, W.; Schneeweiss, A.; Rezai, M.; Lorenz, R.; Jäger, B.; Schramm, A.; Häberle, L.; Fasching, P. A.; Friedl, T. W. P.; Beckmann, M. W. und Scholz, C.
(2016):
Toxicity Assessment of a Phase III Study Evaluating FEC-Doc and FEC-Doc Combined with Gemcitabine as an Adjuvant Treatment for High-Risk Early Breast Cancer: the SUCCESS-A Trial.
In: Geburtshilfe und Frauenheilkunde, Bd. 76, Nr. 5: S. 542-550
Janni, W.; Harbeck, N.; Rack, B.; Augustin, D.; Jückstock, J.; Wischnik, A.; Annecke, K.; Scholz, C.; Huober, J.; Zwingers, T.; Friedl, T. W. P. und Kiechle, M.
(2016):
Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.
In: British Journal of Cancer, Bd. 114, Nr. 8: S. 863-871
Janni, W.; Schramm, A.; Friedl, T. W. P.; Schochter, E.; Huober, J.; Rack, B.; Alunni-Fabbroni, M.; Fasching, P. A.; Taran, F.-A.; Hortkopf, A.; Schneeweiss, A.; Mueller, V.; Aktas, B.; Krawczyk, N.; Pantel, K. und Fehm, T.
(2016):
Factors Predicting Discordance in HER2 Phenotype between Primary Tumor and Circulating Tumor Cells in Women with Metastatic Breast Cancer.
In: Oncology Research and Treatment, Bd. 39: S. 47
Jaeger, B. A. S.; Jückstock, Julia K.; Andergassen, Ulrich; Salmen, J.; Schochter, F.; Fink, V.; Alunni-Fabbroni, Marianna; Rezai, M.; Beck, Th.; Beckmann, M. W.; Friese, K.; Friedl, T. W. P.; Janni, W. und Rack, B.
(2014):
Evaluation of Two Different Analytical Methods for Circulating Tumor Cell Detection in Peripheral Blood of Patients with Primary Breast Cancer.
In: BioMed Research International, Bd. 2014, 491459
[PDF, 1MB]